Navigation Links
Amicus Therapeutics Announces Third Quarter 2008 Financial Results
Date:11/3/2008

Amicus Makes Steady Progress Toward Achievement of Milestones

CRANBURY, N.J., Nov. 3 /PRNewswire-FirstCall/ -- Amicus Therapeutics (Nasdaq: FOLD) today announced financial results for the third quarter of 2008. On a reported basis calculated in accordance with U.S. Generally Accepted Accounting Principles (GAAP), Amicus announced a net loss attributable to common stockholders of $0.36 per share ($0.29 per share on a non-GAAP basis) for the three months ended September 30, 2008. As of September 30, 2008, cash, cash equivalents, and marketable securities totaled $136.3 million.

"The third quarter of 2008 was another quarter of strong progress for Amicus as we focused on clinical and regulatory execution on our three lysosomal storage disease programs," said John F. Crowley, President and CEO of Amicus Therapeutics. "In recent months, we have continued the process with regulatory authorities in the United States and Europe in order to define the global development plan for Amigal(TM) in Fabry, and we remain on track to provide an update by the end of the year. In our Gaucher and Pompe disease programs, we continue to focus on advancing our ongoing Phase 2 clinical trials with the goal of reporting data in Gaucher in 2009. Finally, our financial position remains strong based on a healthy balance sheet and on the economics from our strategic alliance with Shire, which funds 50% of development costs for our lead programs in addition to success-based clinical and regulatory milestone payments."

Program Advancements

Fabry Disease:

Amigal (migalastat hydrochloride) is an investigational, oral therapeutic being developed for the treatment of Fabry disease. Amicus, along with its partner Shire Human Genetic Ther
'/>"/>

SOURCE Amicus Therapeutics
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Amicus Therapeutics Announces Third Quarter 2008 Results Release Date
2. Amicus Therapeutics to Present at the 2008 UBS Global Life Sciences Conference
3. Amicus Therapeutics Opens Research Facility in San Diego
4. Amicus Therapeutics to Present at the 2008 BioCentury NewsMakers in the Biotech Industry Conference
5. Amicus Therapeutics Announces Second Quarter 2008 Results Release Date
6. Amicus Therapeutics Announces First Quarter 2008 Financial Results
7. Amicus Therapeutics to Present at the Morgan Stanley Global Healthcare Unplugged Conference
8. Amicus Therapeutics Presents Positive Data from Phase 2 Clinical Trial of Plicera(TM) for Gaucher Disease
9. Amicus Therapeutics to Present at the BIO CEO & Investor Conference 2008
10. Amicus Therapeutics to Present at the Merrill Lynch Global Pharmaceutical, Biotechnology & Medical Device Conference
11. Amicus Therapeutics Announces Fourth Quarter and Full Year 2007 Financial Results & Program Advancements
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... BioPlus Specialty Pharmacy (BioPlus), one of ... Nick Maroulis, Pharm.D. to the newly created position of ... this position, Dr. Maroulis will continue to manage the ... our multi-site pharmacies as the company expands. Dr. Maroulis ... time he has served in many different capacities in ...
(Date:12/19/2014)... -- Decision Resources Group finds that the Latin American ... compound annual growth rate through 2023. This is primarily ... increasing adoption of dental implants. Growing aesthetic consciousness in ... demand for dental biomaterials because they can improve the ... Other key findings from Decision Resources Group,s coverage ...
(Date:12/19/2014)... December 18, 2014 LayerBio is an ... and wound care. The National Eye Institute (NEI) at ... a Phase I SBIR grant to develop a drug-eluting ... the most common cause of vision loss in people ... worldwide. According to Dr. Ken Mandell, LayerBio’s Founder and ...
(Date:12/19/2014)... In contrast to traditional LED lights where the ... uses proprietary LED technology to incorporate their spectra in ... is critical in low proximity installations. The Valoya L-series ... lifetime which is up to four times longer than ... cost was clearly higher when compared to traditional fluorescent ...
Breaking Biology Technology:BioPlus Specialty Pharmacy Promotes Dr. Nick Maroulis to Vice President of Specialty Pharmacy Services 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 2Latin American Dental Biomaterial Market Will Expand at a 12 Percent Annual Growth Rate Through 2023 3LayerBio Awarded NIH Grant to Develop a Drug Delivery Device for Cataract Surgery 2
... Isolation of Coxiella Burnetii Genomic DNA from Goat Placenta, Mouse Spleen, , ... , , , , , , ... TOURS, Unit de Pathologie Infectieuse et Immunologie, , 37380 NOUZILLY FRANCE , ... , , , , , , ...
... , , , , , , , ... single-stranded DNA may be improved through the use of PLG. (3) , , ... , ... hours, 50 ml culture; stored at 4 C for no more than 3 days) , ...
... , , Bacteria, gram negative , , ... href="http://www.biocompare.com/techart.asp?id=575">Actinobacillus , pleuropnomoniae , ... href="http://www.biocompare.com/techart.asp?id=576">Actinomyces , viscosus <A , ... <A , ...
Cached Biology Technology:EppendorfPerfect gDNA Blood Mini Kit 2EppendorfPerfect gDNA Blood Mini Kit 3EppendorfPerfect gDNA Blood Mini Kit 4EppendorfPerfect gDNA Blood Mini Kit 5M13/Phagemid DNA Extraction Protocol 2Eppendorf Multiporator Transfection Protocols for Eukaryotic , Cells 2Eppendorf Multiporator Transfection Protocols for Eukaryotic , Cells 3Eppendorf Multiporator Transfection Protocols for Eukaryotic , Cells 4Eppendorf Multiporator Transfection Protocols for Eukaryotic , Cells 5Eppendorf Multiporator Transfection Protocols for Eukaryotic , Cells 6Eppendorf Multiporator Transfection Protocols for Eukaryotic , Cells 7
(Date:12/19/2014)... , Dec. 18, 2014 Research and Markets ... addition of the "iPhone 5S Fingerprint Sensor ... report to their offering. ... acquisition of AuthenTec in July 2012, Apple introduced ... It is currently the only device of Apple ...
(Date:12/19/2014)... --  LaunchKey , the first decentralized mobile authentication and ... Things era, today announced the close of $3 million ... by Metamorphic Ventures with participation from ENIAC Ventures, Crosslink ... LaunchKey has raised $4 million to date, and will ... bring LaunchKey to market in 2015. LaunchKey ...
(Date:12/17/2014)...  HITLAB SM announced today its completion ... confirm its adherence to current U.S. Food and ... to conduct regulated smart device and smart phone ... safety and research quality. "HITLAB is ... delivery with innovative technology," said Laura Pugliese ...
Breaking Biology News(10 mins):iPhone 5S Fingerprint Sensor - Apple/AuthenTec TMDR92 & Sapphire - Technology Report 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 2LaunchKey Raises $3 Million in Additional Funding Led by Metamorphic Ventures 3HITLAB Completes GCP Audit for FDA Smart Device & App Compliance 2
... University of Texas M. D. Anderson Cancer Center have significantly ... process of self-destruction - an advance they say may help ... , In the June 30 issue of the journal Cell, ... a cell to prevent it from undergoing apoptosis, or programmed ...
... for decades, but how plants produce and distribute auxin has ... of California, San Diego have found the solution, which has ... in the July 1 issue of the journal Genes and ... genes, and shows that each gene is switched on at ...
... crayfish - a voracious, bullying exotic that has visited ecological ... its match. , Since its introduction to Wisconsin waters sometime ... lakes and streams, clear cutting the underwater forests that are ... of water after another and scooping up fish eggs like ...
Cached Biology News:Researchers find molecular 'brake' to cell death 2Researchers find molecular 'brake' to cell death 3UC San Diego biologists solve plant growth hormone enigma 2UC San Diego biologists solve plant growth hormone enigma 3Study shows hope for ridding lakes of clawed invader 2Study shows hope for ridding lakes of clawed invader 3
... be induced prior to DNA purification increasing ... of single-copy BACs with the high yields ... The kits provide the linearized vector and ... system) necessary to create a 10X human ...
... content or with significant secondary structure are ... subjected to PCR result in little or ... be increased by the addition of enhancing ... an effective PCR enhancer for GC-rich templates., ...
...
... EPICENTREs patented MasterAmp™ 10X PCR Enhancer ... and allows improved sensitivity and specificity ... Using MasterAmp PCR Enhancer in PCR ... DNA melting, increases enzyme?s thermal stability, ...
Biology Products: